C4B and B-cell chronic lymphocytic leukemia: Moreover, BAX-mutated CH has been shown to arise after the treatment with a BCL-2 inhibitor, venetoclax, in patients with chronic lymphocytic leukemia (CLL) (89), strongly reflecting the evolutionary dynamics in response to targeting antiapoptotic proteins.